Literature DB >> 16950226

Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Incarnation Aubert1, Céline Guigoni, Qin Li, Sandra Dovero, Bernard H Bioulac, Christian E Gross, Alan R Crossman, Bertrand Bloch, Erwan Bezard.   

Abstract

BACKGROUND: A role for enhanced opioid peptide transmission has been suggested in the genesis of levodopa-induced dyskinesia. However, basal ganglia nuclei other than the striatum have not been regarded as potential sources, and the opioid precursors have never been quantified simultaneously with the levels of opioid receptors at the peak of dyskinesia severity.
METHODS: The levels of messenger RNA (mRNA) encoding the opioid precursors preproenkephalin-A and preproenkephalin-B in the striatum and the subthalamic nucleus and the levels of mu, delta, and kappa opioid receptors were measured within the basal ganglia of four groups of nonhuman primates killed at the peak of effect: normal, parkinsonian, parkinsonian chronically-treated with levodopa without exhibiting dyskinesia, and parkinsonian chronically-treated with levodopa showing overt dyskinesia.
RESULTS: Dyskinesia are associated with reduction in opioid receptor binding and specifically of kappa and mu receptor binding in the globus pallidus internalis (GPi), the main output structure of the basal ganglia. This decrease was correlated with enhancement of the expression of preproenkephalin-B mRNA but not that of preproenkephalin-A in the striatum and the subthalamic nucleus.
CONCLUSIONS: Abnormal transmission of preproenkephalin-B-derived opioid coming from the striatum and the subthalamic nucleus converges upon GPi at the peak of dose to induce levodopa-induced dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950226     DOI: 10.1016/j.biopsych.2006.06.038

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  26 in total

1.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

Review 2.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 3.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

4.  Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.

Authors:  Agnes Nadjar; Jonathan M Brotchie; Celine Guigoni; Qin Li; Shao-Bo Zhou; Gui-Jie Wang; Paula Ravenscroft; François Georges; Alan R Crossman; Erwan Bezard
Journal:  J Neurosci       Date:  2006-08-23       Impact factor: 6.167

5.  The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Authors:  Heather Cox; Daniel M Togasaki; Li Chen; J William Langston; Donato A Di Monte; Maryka Quik
Journal:  Exp Neurol       Date:  2007-02-03       Impact factor: 5.330

6.  Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.

Authors:  Pedro Barroso-Chinea; Erwan Bezard
Journal:  Front Neuroanat       Date:  2010-09-14       Impact factor: 3.856

7.  Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.

Authors:  Daniella Rylander; Alessandra Recchia; Flora Mela; Andrzej Dekundy; Wojciech Danysz; M Angela Cenci
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

8.  Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

Authors:  Jenny E Westin; Linda Vercammen; Elissa M Strome; Christine Konradi; M Angela Cenci
Journal:  Biol Psychiatry       Date:  2007-07-26       Impact factor: 13.382

9.  µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Erwan Bezard; Qin Li; Heather Hulme; Elva Fridjonsdottir; Anna Nilsson; Elsa Pioli; Per E Andren; Alan R Crossman
Journal:  J Neurosci       Date:  2020-07-20       Impact factor: 6.167

10.  Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.

Authors:  Olivier Berton; Céline Guigoni; Qin Li; Bernard H Bioulac; Incarnation Aubert; Christian E Gross; Ralph J Dileone; Eric J Nestler; Erwan Bezard
Journal:  Biol Psychiatry       Date:  2009-05-28       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.